Armed ImmunoCytokine Platform, AIC™

      Based on deep understanding of immunology and the ...

      more >>

      Armed Innate-effector Multispecific Platform, AIM™

      By activation of innate effectors (i.e. NK and γδT...

      more >>

      ADCC Enhanced Antibody Platform, AEA™

      Fucose modification is one of the most important f...

      more >>
      About SunHo
      • 20+

        innovative and differentiated R&D pipelines
      • 150

      • 85

        R&D members with 70% of master degree and above
      • 4500m2

        square meters of workshop
      more >>


      SUNHO (China) BioPharmaceutical Co., Ltd. (hereinafter referred to as SunHo) is located in Nanjing Economic and Technological Development Zone, Jiangsu Province, China. SunHo is a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of world-class innovative biotherapeutics and focuses on the field of cancer immunotherapy, autoimmune diseases and neurodegenerative diseases.

      With multiple proprietary and patented platforms, such as Armed ImmunoCytokine Platform (AIC?) , Armed Innate-effector Multispecific Platform (AIM?) , ADCC Enhanced Antibody Platform (AEA?), SunHo has developed more than 20 globally innovative and differentiated R&D pipelines in oncology/immunology with 4 in clinical stage, 4 in IND application, 6 in preclinical, and many innovative projects in the early R&D stage. We are striving to develop the next generation and best-in-class medicines to address unmet medical needs with accessibility globally.......